Peter Ding, Allorion Therapeutics co-founder and CEO

A fledg­ling transpa­cif­ic biotech grabs a launch round to dive in­to on­col­o­gy and au­toim­mune re­search

Pre­ci­sion-med biotech Al­lo­ri­on Ther­a­peu­tics is ex­pand­ing — and now has tens of mil­lions of dol­lars more to work with.

The Nat­ick, MA-based com­pa­ny an­nounced in a state­ment this morn­ing that it closed a Se­ries A round, bring­ing in $40 mil­lion. Shang­hai VC Qim­ing Ven­ture Part­ners led the round, which al­so in­cludes a num­ber of both new and old in­vestors — Oc­ta­gon Cap­i­tal, IDG Cap­i­tal and TF Cap­i­tal, to name a few.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Vice President

Alexandria Real Estate Equities

San Francisco, CA, USA